1,003
Views
4
CrossRef citations to date
0
Altmetric
Research Paper

Assessment of seroprevalence against poliovirus among Italian adolescents and adults

ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, &
Pages 677-682 | Received 05 Sep 2018, Accepted 05 Nov 2018, Published online: 20 Dec 2018

References

  • World Health Organization (WHO). Polio vaccines: WHO position paper. Wkly Epidemiol Rec. 2016;91(12):145–168.
  • Sutter RW, Pallansch MA, Sawyer LA, Cochi SL, Hadler SC. Defining surrogate serologic tests with respect to predicting protective vaccine efficacy: poliovirus vaccination. Ann N Y Acad Sci. 754;1995:289–299.
  • Sutter RW, Kew OM, Cochi SL, Aylward RB. Poliovirus vaccine-live. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. Philadelphia, PA: Elsevier-Saunders; 2017. p. 866–917.
  • Global Polio Eradication Initiative. [ Accessed 2018 Feb 2]. http://polioeradication.org/where-we-work/polio-endemic-countries/
  • Tafuri S, Prato R, Martinelli D, Calvario A, Bozzi A, Labianca M, Patti A, Lopalco PL, Germinario C. Serological survey on immunity status against polioviruses in children and adolescents living in a border region, Apulia (Southern Italy). BMC Infect Dis. 2008;8:.150. doi:10.1186/1471-2334-8-150.
  • Majori S, Baldo V, Poli A, Riolfatti M, Alborino F, Bonello C, Frau S, Baldovin T, Dal Zotto A, Romano G, et al. Immunity to poliovirus among children and the elderly in north-east Italy. J Prev Med Hyg. 2006;47(1):12–15.
  • Baldo V, Baldovin T, Cocchio S, Lazzari R, Saracino E, Bertoncello C, Buja A, Trevisan A. Seroepidemiology of polioviruses among university students in northern Italy. Clin Vaccine Immunol. 2012;19(8):1292–1295. doi:10.1128/CVI.00054-12.
  • Conferenza permanente per i rapporti tra lo Stato, le Regioni e le Province Autonome di Trento e Bolzano. Accordo tra il Ministero della Salute, le Regioni e le Province Autonome di Trento e Bolzano sulle modifiche al calendario della vaccinazione antipoliomielitica; 2002 May 30. [Italian]. 10.1044/1059-0889(2002/er01)
  • European Centre for Disease Prevention and Control. Wild-type poliovirus 1 transmission in Israel – what is the risk to the EU/EEA? Stockholm, Sweden: ECDC; 2013. [ Accessed 2018 Mar 2]. http://ecdc.europa.eu/en/publications/Publications/polio-risk-assessment-transmission-in-Israel.pdf
  • Wallace GS, Curns AT, Weldon WC, Oberste MS. Seroprevalence of poliovirus antibodies in the United States population, 2009-2010. BMC Public Health. 2016;16:.721. doi:10.1186/s12889-016-3386-1.
  • Reinheimer C, Friedrichs I, Rabenau HF, Doerr HW. Deficiency of immunity to poliovirus type 3: a lurking danger? BMC Infect Dis. 2012;12:.24. doi:10.1186/1471-2334-12-24.
  • Frantzidou F, Diza E, Halkia D, Antoniadis A. A seroprevalence study of poliovirus antibody in the population of northern Greece. Clin Microbiol Infect. 2005;11(1):68–71. doi:10.1111/j.1469-0691.2004.00998.x.
  • Pires de Miranda M, Carmo Gomes M, Rebelo de Andrade H. Seroprevalence of antibodies to poliovirus in individuals living in Portugal, 2002. Euro Surveill. 2007;12(6):E7–E8.
  • van der Maas NA, Mollema L, Berbers GA, van Rooijen DM, van der Avoort HG, Conyn-Van Spaendonck MA, de Melker HE, van der Klis FR. Immunity against poliomyelitis in the Netherlands, assessed in 2006 to 2007: the importance of completing a vaccination series. Euro Surveill. 2014;19(7):20705. doi:10.2807/1560-7917.ES2014.19.7.20705.
  • Martin N, Paterson BJ, Durrheim DN. Australia’s polio risk. Commun Dis Intell Q Rep. 2014;38(2):E107–13.
  • Wallace GS, Pahud BA, Weldon WC, Curns AT, Oberste MS, Harrison CJ. Seroprevalence of poliovirus antibodies in the Kansas City metropolitan area, 2012-2013. Hum Vaccin Immunother. 2017;13(4):776–783. doi:10.1080/21645515.2016.1255386.
  • Roivainen M, Montagnon B, Chalumeau H, Murray M, Wimmer E, Hovi T. Improved distribution of antigenic site specificity of poliovirus-neutralizing antibodies induced by a protease-cleaved immunogen in mice. J Virol. 1990;64(2):559–562.
  • Nijsten D, Carrillo-Santisteve P, Miglietta A, Ruitenberg J, Lopalco PL. Is EU/EEA population protected from polio? Hum Vaccin Immunother. 2015;11(9):2123–2131. doi:10.1080/21645515.2015.1016673.
  • Veronesi L, Affanni P, Verrotti Di Pianella C, Colucci ME, Tanzi ML. Immunity status against poliomyelitis in childbearing women in a province of northern Italy. A cross-sectional analysis. Ann Ig. 2013;25:427–433. doi:10.7416/ai.2013.1944.
  • Ministero della Salute. Piano Nazionale della Prevenzione Vaccinale 2017-2019. G.U. Serie Generale, n. 41 del 18 febbraio 2017 [Italian].
  • De Donno A, Kuhdari P, Guido M, Rota MC, Bella A, Brignole G, Lupi S, Idolo A, Stefanati A, Del Manso M, et al. Study Group on seroepidemiology. Has VZV epidemiology changed in Italy? Results of a seroprevalence study. Hum Vaccin Immunother. 2017;13(2):385–390. doi:10.1080/21645515.2017.1264828.
  • Foiadelli T, Savasta S, Battistone A, Kota M, Passera C, Fiore S, Bino S, Amato C, Lozza A, Marseglia GL, et al. Nucleotide variation in Sabin type 3 poliovirus from an Albanian infant with agammaglobulinemia and vaccine associated poliomyelitis. BMC Infect Dis. 2016;16:277. doi:10.1186/s12879-016-1587-y.
  • World Health Organization (WHO). Polio laboratory manual. 4th ed. Geneva, Switzerland: WHO/IVB/04.10; 2004.
  • World Health Organization (WHO). Manual for the virological investigation of polio. Geneva, Switzerland: WHO/EPI/GEN/97.01; 1997.